SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Harpoon Therapeutics, Inc. (“Harpoon”), a clinical-stage immunotherapy
company developing a novel class of T cell engagers, announced today the
pricing of its initial public offering of 5,400,000 shares of its common
stock at a price to the public of $14.00 per share. The gross proceeds
to Harpoon from the offering, before deducting the underwriting
discounts and commissions and offering expenses payable by Harpoon, are
expected to be $75.6 million. The shares are expected to begin trading
on the Nasdaq Global Select Market on February 8, 2019 under the symbol
“HARP.” The offering is expected to close on February 12, 2019, subject
to customary closing conditions. In addition, Harpoon has granted the
underwriters a 30-day option to purchase up to an additional 810,000
shares of common stock.
Citigroup and SVB Leerink are acting as joint book-running managers for
the offering. Canaccord Genuity and Wedbush PacGrow are acting as
co-managers for the offering.
A registration statement relating to these securities has been filed
with the Securities and Exchange Commission and was declared effective
on February 7, 2019. The offering is being made only by means of a
prospectus. Copies of the final prospectus relating to the offering may
be obtained, when available, from: Citigroup Global Markets Inc., c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY
11717, or by telephone at (800) 831-9146; or SVB Leerink LLC, Attention:
Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110,
by telephone at (800) 808-7525, ext. 6132, or by e-mail at syndicate@svbleerink.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of, these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of such state or jurisdiction.
About Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immunotherapy company
developing a novel class of T cell engagers that harness the power of
the body’s immune system to treat patients suffering from cancer and
other diseases. T cell engagers are engineered proteins that direct a
patient’s own T cells to kill target cells that express specific
proteins, or antigens, carried by the target cells. Using its
proprietary Tri-specific T cell Activating Construct™ (“TriTAC”),
platform, Harpoon is developing a pipeline of novel T cell engagers, or
TriTACs, initially focused on the treatment of solid tumors and
hematologic malignancies.
Contacts
Harpoon Therapeutics, Inc.
Georgia Erbez
Chief Financial
Officer
650-443-7400
media@harpoontx.com
Kinkead
Communications, Inc.
Susan Kinkead
415-509-3610
susan@kinkeadcomm.com
Westwicke
Partners, LLC.
Robert H. Uhl
Managing Director
858-356-5932
robert.uhl@westwicke.com
